ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 GP28 | DOI: 10.1530/endoabs.63.GP28

The synergistic impact of apolipoprotein B/ A-1 and lipoprotein (a) on coronary artery calcification

Chul Woo Ahn1, Arim Choi1, Jung Hye Kim1, Kahui Park1, Sang Bae Lee1, Yusik Kim2, Ji Sun Nam1, Shinae Kang1 & Jong Suk Park1


1Division of Endocrinology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; 2Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, Republic of Korea.


Objective: Apolipoprotein B/Apolipoprotein A-1 ratio (Apo B/Apo A-1) and lipoprotein (a) (Lp(a)) are known to be associated with atherosclerotic vascular disease. We investigated the influence of Apo B/Apo A-1 and Lp(a) on coronary artery calcification (CAC) among healthy Korean adults.

Methods: A total of 1081 participants underwent cardiac computed tomography in health promotion center were enrolled. Anthropometric profiles and multiple cardiovascular risk factors, including Apo B, Apo A-1, and Lp(a) were measured were measured. Multi-detector CT was used to measure coronary artery calcium score (CACS) and CACS>0 was defined as the presence of CAC. Adjusted Odds ratios for the presence of CAC according to Lp(a) and Apo B/Apo A-1 tertiles were estimated using logistic regression.

Results: Subjects were grouped according to Lp(a) and Apo B/Apo A-1 levels. There were significant differences in cardiovascular parameters among the groups and the prevalence of CAC significantly increased with Lp(a) and Apo B/Apo A-1 levels. In the logistic regression analysis adjusted for multiple risk factors, odds ratio (95% CI) for the prevalence of CAC comparing the lowest Lp(a) and Apo B/Apo A-1 group to the highest group was 2.554 (1.256–5.201) (P<0.05).

Conclusion: These results show that Apo B/Apo A-1 and Lp(a) have a synergistic impact on prevalence of CAC, which suggests that individuals with elevated Lp(a) and Apo B/Apo A-1, should be more closely monitored to allow a better risk assessment for subclinical atherosclerosis.

Article tools

My recent searches

No recent searches.